MINRIN® Orally Disintegrating Tablet (Fast Dissolving Desmopressin) and Tablets in Treatment of Primary Nocturnal Enuresis

MINRIN® Orally Disintegrating Tablet (Fast Dissolving Desmopressin) and Tablets in Treatment of Primary Nocturnal Enuresis With Special Focus on Patient Satisfaction

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01368913

Acronym

MELT

Enrollment

138

Registered

2011-06-08

Start date

2011-06-30

Completion date

2013-05-31

Last updated

2013-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nocturnal Enuresis

Brief summary

Desmopressin in treatment of nocturnal enuresis (bedwetting).

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

5 Years to No maximum

Healthy volunteers

Inclusion criteria

* Treatment of primary nocturnal enuresis within an overall therapeutical concept, eg, in cases of failure of other non-medicinal therapies or with indication of a medicinal therapy caused by nocturnal ADH deficiency * The patients and their parents have been informed about the study and have given their written consent for participation.

Exclusion criteria

* The prescription of Minirin® tablets / Minirin® orally disintegrating tablet (fast dissolving desmopressin) is contraindicated

Design outcomes

Primary

Measure	Time frame
Assessment of patient and parent satisfaction	3 months

Secondary

Measure	Time frame
Number of wet nights	3 months
Assessment of drinking volume	3 months
Assessment of urine volume	3 months
Assessment of patient compliance	3 months

Countries

Germany

Outcome results